Daily Stock Analysis, CBMG, Cellular Biomedicine Group Inc, priceseries

Cellular Biomedicine Group Inc. Daily Stock Analysis
Stock Information
Open
19.74
Close
19.75
High
19.75
Low
19.73
Previous Close
19.75
Daily Price Gain
0.00
YTD High
19.75
YTD High Date
Feb 18, 2021
YTD Low
17.60
YTD Low Date
Jan 28, 2021
YTD Price Change
1.50
YTD Gain
8.22%
52 Week High
19.75
52 Week High Date
Feb 18, 2021
52 Week Low
11.48
52 Week Low Date
Mar 16, 2020
52 Week Price Change
3.59
52 Week Gain
22.22%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 19. 2017
7.35
Jul 10. 2017
8.59
14 Trading Days
16.87%
Link
LONG
Aug 28. 2017
9.00
Sep 15. 2017
10.47
13 Trading Days
16.38%
Link
LONG
Oct 30. 2017
9.80
Nov 8. 2017
10.41
7 Trading Days
6.22%
Link
LONG
Jan 2. 2018
12.50
Jan 23. 2018
18.50
14 Trading Days
48.00%
Link
LONG
Jun 21. 2018
18.05
Jul 5. 2018
19.35
9 Trading Days
7.19%
Link
LONG
Nov 6. 2018
14.32
Nov 20. 2018
16.02
10 Trading Days
11.87%
Link
LONG
Jun 19. 2020
13.24
Jul 8. 2020
15.38
12 Trading Days
16.15%
Link
Company Information
Stock Symbol
CBMG
Exchange
NasdaqGM
Company URL
http://www.cellbiomedgroup.com
Company Phone
(408) 973-7884
CEO
Bizuo Liu
Headquarters
California
Business Address
19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO, CA 95014
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001378624
About

Cellular Biomedicine Group, Inc. is a biopharmaceutical company. The company engages in the development of treatments for degenerative and cancerous diseases utilizing proprietary cell-based technologies. Its technology include immune cell therapy for treatment of a range of cancers using Chimeric Antigen Receptor T cell, cancer vaccine, and T Central Memory cell technology; and human adipose-derived mesenchymal progenitor cells for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. Cellular Biomedicine Group was founded in 2009 and is headquartered in Cupertino, CA.

Description

Cellular Biomedicine Group, Inc., a biomedicine company, develops treatments for cancerous and degenerative diseases in Greater China. The company operates through two segments, Biomedicine and Consulting. It focuses on developing and marketing cell-based therapies to treat serious chronic and degenerative diseases, such as cancer, osteoarthritis, tissue damage, spinal muscular atrophy, various inflammatory diseases, and joint degeneration and metabolic diseases. The company develops treatments utilizing proprietary cell technologies comprising tumor cell specific dendritic cells for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint disease; human umbilical cord-derived mesenchymal progenitor cells; human embryo-derived motor neuron progenitor precursor cells; and human embryo-derived neuronal progenitor precursor cells for the treatment of central nervous system diseases. It also provides consulting services to companies who seek access to the U.S. capital markets. The company is headquartered in Palo Alto, California.